Exelixis, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EXEL research report →
Companywww.exelixis.com
Exelixis, Inc. , an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
- CEO
- Michael Morrissey
- IPO
- 2000
- Employees
- 1,147
- HQ
- Alameda, CA, US
Price Chart
Valuation
- Market Cap
- $12.45B
- P/E
- 15.35
- P/S
- 5.24
- P/B
- 6.61
- EV/EBITDA
- 12.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 96.44%
- Op Margin
- 39.43%
- Net Margin
- 35.08%
- ROE
- 40.21%
- ROIC
- 35.01%
Growth & Income
- Revenue
- $2.32B · 6.98%
- Net Income
- $782.57M · 50.13%
- EPS
- $2.88 · 60.00%
- Op Income
- $872.19M
- FCF YoY
- 33.22%
Performance & Tape
- 52W High
- $51.63
- 52W Low
- $33.76
- 50D MA
- $44.65
- 200D MA
- $42.06
- Beta
- 0.39
- Avg Volume
- 2.83M
Get TickerSpark's AI analysis on EXEL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | MORRISSEY MICHAEL | other | 124,047 |
| May 15, 26 | MORRISSEY MICHAEL | other | 128,497 |
| May 18, 26 | MORRISSEY MICHAEL | other | 124,047 |
| May 15, 26 | Senner Christopher J. | other | 40,892 |
| May 18, 26 | Senner Christopher J. | sell | 34,901 |
| May 15, 26 | Haley Patrick J. | other | 33,265 |
| May 15, 26 | Hefti Brenda | other | 6,411 |
| May 18, 26 | Hefti Brenda | sell | 6,625 |
| May 15, 26 | Aftab Dana | other | 30,578 |
| May 7, 26 | Beckerle Mary C | other | 3,856 |
Our EXEL Coverage
We haven't published any research on EXEL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EXEL Report →